Drugs / Bev-ICG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06430372 | Jul 2023 → May 2025 overdue | digestive system carcinoma, gastrointestinal polyp | Institute of Automation, Chinese Academy of Sciences | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bev-ICG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06430372 ↗ |
| Modality | Diagnostic / imaging agent | “We are using a VEGF-A targeting fluorescent probe and a NIR-II fluorescent endoscope to help detect abnormal tissues that are hard to see by the naked eye.” NCT06430372 ↗ |
| Route | Topical | “The patients will receive a topical administration of probe (Bev-ICG) during the endoscopy.” NCT06430372 ↗ |
| Target | VEGFA | “Probe targeting VEGF-A that is topically administrated during the endoscopy” NCT06430372 ↗ |